EU regulator supports a label expansion of Novo Nordisk’s diabetes drug to reflect its potential to lower the risk of ...

Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

During the quarter, the Harbor International Compounders Fund returned 4.40%, underperforming its primary benchmark.

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

In the third quarter of its fiscal year 2025, ended Oct. 31, Veeva Systems' revenue increased by 13% year over year to $699.2 ...

Novo Nordisk's Lotte Bjerre Knudsen says her determination is a key part of the success, but she also stays humble.

Novo Holdings, the investment arm of the Novo Nordisk Foundation, has gained approval from the European Commission (EC) for ...

Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Exxon ...

Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.

Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and ...